Anti-inflammatory drugs degradation during LED-UV 365 photolysis of free chlorine: roles of reactive oxidative species and formation of disinfection by-products
ight-emitting diode (LED) which are environmentally friendly with longer life compared to traditional mercury lamp. This study investigated the anti-inflammatory drugs non-steroidal (NSAIDs) – phenacetin (PNT) and acetaminophen (ACT) – the deletion for LED-UV (365 nm) photolysis of free available chlorine (FAC). PNT degradation and ACT for LED-UV365 / FAC treatment at pH 5.5 to 8.5 followed pseudo-first-order kinetics. The presence of hydroxyl radicals (OH ·), reactive chlorine species (RCS), and ozone (O3, change of O (3P)) filtered by using a scavenger ethanol (EtOH), tert-butanol (TBA), and 3- Buten-2ol, and 4-hydroxy-2,2,6,6-tetramethylpiperidine (TEMP), and is measured by the kinetics of competition with probing compound nitrobenzene (NB), benzoic acid (BA), 1,4-dimethoxybenzene (Dmob). Higher pH will cause a decrease ·
OH contribution and increased contribution to the PNT and ACT FAC degradation. It has been determined that the contribution of PNT and ACT O3 degradation of less than 5% for all pH, and O3 (P) react to EtOH with second-order constant of 1.52 × 109 M-1s-1. LED-UV365 / FAC system reduces the formation of five typical CX3-R type of disinfection by-products (DBPs) as well as cytotoxicity and genotoxicity of water samples at pH 5.5 and 8.5, compared with FAC alone.
A decrease in the formation of DBPs resulting from the rapid decomposition of the irradiation LED FAC-UV365. A decent reaction path forming DBPs in LED-systems UV365 / FAC checked by density functional theory (DFT). To decay FAC for LED-UV365 / FAC effluents from waste water, in 15 minutes the rest of the FAC was 0.8 mg / L (lower than the limit of 0.2 mg / L) after the initial FAC was 2.0 mg / L. the results showed that more testing on the balance of the pollutant removal efficiency targets, FAC residual and fees should be explored in a system of LED-UV365 / FAC for the application.
Anti-inflammatory drugs degradation during LED-UV 365 photolysis of free chlorine: roles of reactive oxidative species and formation of disinfection by-products
Anti-Cancer Effect of 3-Hydroxy-β-Ionone Identified from Moringa oleifera Lam. Man leaves 15 squamous cell carcinoma cells
Squamous cell carcinoma is the most common type of cancer worldwide head and neck. Radiation and chemotherapy common treatment for patients; However, these drugs can have side effects and tumors develop drug resistance. effective treatments still require improvements for cancer patients. Here, we examined the effects of anti-cancer properties of Moringa oleifera (MO) Lam.
leaf extract and its fractions, 3-hydroxy-β-ionone in SCC15 cells. SCC15 treated with and without MO leaf extract and its fractions. MTT assay was used to determine cell viability in SCC15. cell cycle and apoptosis was evaluated by Muse ™ cell analyzer. colony formation and wound closure SCC15 analysis conducted in 6-well plates.
Description: TNFRSF10B (Tumor necrosis factor receptor superfamily, member 10b) has many names, including DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL R2, KILLER/DR5. The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces apoptosis signal. Mice have a homologous gene, tnfrsf10b, that has been essential in the elucidation of the function of this gene in humans. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. By analysis of radiation hybrid panels, Walczak et al.(1997) mapped the gene to chromosome 8p22-p21. Northern blot analysis indicated that TRAIL R2 was expressed as a 4.4-kb mRNA in all tissues tested, with the highest levels of expression in peripheral blood lymphocytes, spleen, and ovary.
Description: TNFRSF10B (Tumor necrosis factor receptor superfamily, member 10b) is a human gene. It is also known as DR5 (Death Receptor 5), CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5. The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces apoptosis signal. Mice have a homologous gene, tnfrsf10b that has been essential in the elucidation of the function of this gene in humans. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.By analysis of radiation hybrid panels, this gene is mapped to chromosome 8p22-p21. Northern blot analysis indicated that TRAILR2 was expressed as a 4.4-kb mRNA in all tissues tested, with the highest levels of expression in peripheral blood lymphocytes, spleen, and ovary.
Description: TNFRSF10B (Tumor necrosis factor receptor superfamily, member 10b) is a human gene. It is also known as DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5. The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces apoptosis signal. Mice have a homologous gene, tnfrsf10b that has been essential in the elucidation of the function of this gene in humans. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.By analysis of radiation hybrid panels, this gene is mapped to chromosome 8p22-p21. Northern blot analysis indicated that TRAILR2 was expressed as a 4.4-kb mRNA in all tissues tested, with the highest levels of expression in peripheral blood lymphocytes, spleen, and ovary.
Description: The protein encoded by the TNFRSF10B is a member of the TNF-receptor superfamily, and contains an intracellular death domain. Death receptor 5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. [RefSeq]
Description: Tumor necrosis factor (TNF) is a pleiotropic cytokine whose function is mediated by two distinct cell surface receptors, designated TNF-R1 and TNF-R2, which are expressed on most cell types. TNF function is primarily mediated through TNF-R1 signaling. Both receptors belong to the growing TNF receptor superfamily which includes Fas antigen and CD40. TNF-R1 contains a cytoplasmic motif, termed the death domain, that has been found to be necessary for the transduction of the apoptotic signal. The death domain is also found in several other receptors, including Fas, DR2 (or TRUNDD), DR3 (death receptor 3), DR4 and DR5. TRUNDD, DR4 and DR5 are receptors for the apoptosis-inducing cytokine TRAIL. A non-death domain-containing receptor, designated decoy receptor (DcR1 or TRID), also specifically associates with TRAIL and may play a role in cellular resistance to apoptotic stimuli.
Description: Tumor necrosis factor (TNF) is a pleiotropic cytokine whose function is mediated by two distinct cell surface receptors, designated TNF-R1 and TNF-R2, which are expressed on most cell types. TNF function is primarily mediated through TNF-R1 signaling. Both receptors belong to the growing TNF receptor superfamily which includes Fas antigen and CD40. TNF-R1 contains a cytoplasmic motif, termed the death domain, that has been found to be necessary for the transduction of the apoptotic signal. The death domain is also found in several other receptors, including Fas, DR2 (or TRUNDD), DR3 (death receptor 3), DR4 and DR5. TRUNDD, DR4 and DR5 are receptors for the apoptosis-inducing cytokine TRAIL. A non-death domain-containing receptor, designated decoy receptor (DcR1 or TRID), also specifically associates with TRAIL and may play a role in cellular resistance to apoptotic stimuli.
Description: Tumor necrosis factor (TNF) is a pleiotropic cytokine whose function is mediated by two distinct cell surface receptors, designated TNF-R1 and TNF-R2, which are expressed on most cell types. TNF function is primarily mediated through TNF-R1 signaling. Both receptors belong to the growing TNF receptor superfamily which includes Fas antigen and CD40. TNF-R1 contains a cytoplasmic motif, termed the death domain, that has been found to be necessary for the transduction of the apoptotic signal. The death domain is also found in several other receptors, including Fas, DR2 (or TRUNDD), DR3 (death receptor 3), DR4 and DR5. TRUNDD, DR4 and DR5 are receptors for the apoptosis-inducing cytokine TRAIL. A non-death domain-containing receptor, designated decoy receptor (DcR1 or TRID), also specifically associates with TRAIL and may play a role in cellular resistance to apoptotic stimuli.
Description: A polyclonal antibody for detection of TNF-R2 from Human, Mouse, Rat. This TNF-R2 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human TNF-R2 at AA range: 350-430
Description: A polyclonal antibody for detection of TNF-R2 from Human, Mouse, Rat. This TNF-R2 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human TNF-R2 at AA range: 350-430
Description: A polyclonal antibody for detection of TNF-R2 from Human, Mouse, Rat. This TNF-R2 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human TNF-R2 at AA range: 350-430
Description: A polyclonal antibody for detection of GABAB R2 from Human, Mouse, Rat. This GABAB R2 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human GABAB R2 around the non-phosphorylation site of S893
Description: A polyclonal antibody for detection of GABAB R2 from Human, Mouse, Rat. This GABAB R2 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human GABAB R2 around the non-phosphorylation site of S893
Description: A polyclonal antibody for detection of GABAB R2 from Human, Mouse, Rat. This GABAB R2 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human GABAB R2 around the non-phosphorylation site of S893
Description: This monoclonal antibody enables sensitive and specific detection of human IL-2 in immunoassays such as ELISA and ELISpot. The antibody is also suitable for detection of IL-2 using Flow cytometry.
Description: This monoclonal antibody enables sensitive and specific detection of human IL-17A in immunoassays such as ELISA and ELISpot. The antibody is also suitable for detection of IL-17A using Flow cytometry.
Description: This monoclonal antibody enables sensitive and specific detection of human IL-1β in immunoassays such as ELISA and ELISpot. The antibody binds to the pro-form and the active form of IL-1β. It does not cross-react with IL-1α.
Description: This monoclonal antibody enables sensitive and specific detection of human IL-1β in immunoassays such as ELISA and ELISpot. The antibody binds to the pro-form and the active form of IL-1β. It does not cross-react with IL-1α.
Description: This monoclonal antibody enables sensitive and specific detection of human IL-1α in immunoassays such as ELISA, ELISpot, and Western blot.
Human IL-1 R antagonist / IL-1RA ELISA kit (4X96T)
Description: Description of target: Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas.;Species reactivity: Human;Application: ELISA;Assay info: Quantitative Colorimentric Sandwich ELISA;Sensitivity: 32 pg/mL
Description: Description of target: This gene encodes a member of the Ser/Thr protein kinase family and the TGFB receptor subfamily. The encoded protein is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with another receptor protein, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation. Mutations in this gene have been associated with Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized.;Species reactivity: Human;Application: ELISA;Assay info: Quantitative Colorimentric Sandwich ELISA;Sensitivity: 16 pg/mL
Description: Description of target: The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein and TNF-receptor 1 form a heterocomplex that mediates the recruitment of two anti-apoptotic proteins, c-IAP1 and c-IAP2, which possess E3 ubiquitin ligase activity. The function of IAPs in TNF-receptor signalling is unknown, however, c-IAP1 is thought to potentiate TNF-induced apoptosis by the ubiquitination and degradation of TNF-receptor-associated factor 2, which mediates anti-apoptotic signals. Knockout studies in mice also suggest a role of this protein in protecting neurons from apoptosis by stimulating antioxidative pathways.;Species reactivity: Human;Application: ELISA;Assay info: Quantitative Colorimentric Sandwich ELISA;Sensitivity: 8 pg/mL
Description: Interleukin-10 (IL-10 or IL10), also known as human cytokine synthesis inhibitory factor(CSIF), is an anti-inflammatory cytokine. In humans IL-10 is encoded by the IL10 gene. It is capable of inhibiting synthesis of pro-inflammatory cytokines like IFN-gamma, IL-2, IL-3, TNFalpha and GM-CSF made by cells such as macrophages and regulatory T-cells.IL-10 also displays potent abilities to suppress the antigen presentation capacity of antigen presenting cells. Kim et al.(1992) showed that the mouse IL 10 gene contains 5 exons and spans about 5.2 kb of genomic DNA. Eskdale et al.(1997) mapped the IL10 gene to the junction between 1q31 and 1q32.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GABA (B) R2 . This antibody is tested and proven to work in the following applications:
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.
×
Apoptotic markers were evaluated by immunoblotting. We found that an extract of moringa and 3-HBI significantly inhibit proliferation of SCC15. In addition, they induced apoptosis and cell cycle arrest in G2 / M phase in SCC15 compared with untreated controls. MO extract and 3-HBI also inhibit the colony formation and cell migration SCC15. In addition, we observed upregulation of cleaved caspase-3 and Bax with downregulation of anti-apoptotic Bcl-2, which shows the induction of apoptosis of cancer cells. Our results show that extracts of MO and 3-HBI supplied anti-cancer properties by inhibiting the progression and induce apoptosis of SCC15.
Chris
